ABUS
Arbutus Biopharma Corporation
NasdaqGSUSDEQUITY
DELAYED
Last price
5.24
▲ 0.47 (9.85%)
MARKET · —
Price
Open
4.99
Prev close
4.77
Day high
5.45
Day low
5.09
Volume
18.05M
Market cap
—
P/E (TTM)
—
52W range
3.49 – 5.45
Trailing performance
Returnvs SPY
1W
+11.56%
+12.9%
1M
+16.55%
+12.8%
3M
+17.34%
+14.2%
6M
+22.01%
+10.9%
YTD
+8.32%
-4.0%
1Y
+49.28%
+29.3%
3Y
+156.65%
+82.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.76
+10.06% from price
SMA 20
4.60
+13.21% from price
SMA 50
4.61
+13.09% from price
SMA 100
4.49
+16.72% from price
SMA 200
4.46
+16.75% from price
EMA 12
4.78
+9.74% from price
EMA 26
4.67
+12.26% from price
EMA 50
4.60
+13.90% from price
RSI (14)
66.9
Neutral
MACD (12,26,9)
0.11
Hist 0.06
ATR (14)
0.23
4.33% of price
Realised vol 30D
46.6%
Annualised
Bollinger upper
5.05
20, 2σ
Bollinger lower
4.16
20, 2σ
50 / 200 cross
Golden
4.61 vs 4.46
Trend bias
Above 200
+16.75%
Risk profile
Beta vs SPY
1.25
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
46.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-25.9%
Peak to trough
Max drawdown 5Y
-63.4%
Peak to trough
ATR 14
0.23
4.33% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · 1d ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 1d ago
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
InvestorsHub · 1d ago
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday
MT Newswires · 1d ago
Sector Update: Healthcare
MT Newswires · 1d ago
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Stocktwits · 1d ago
Arbutus Biopharma Plans Up to $230 Million Modified Dutch Auction Tender Offer
MT Newswires · 1d ago
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
GlobeNewswire · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.